팬젠
Financials
Valuation Metrics
팬젠's Market Cap is ₩645B. At end of 2025 it was ₩757B. Ranked #1608 of 2,421 in KR market (top 66%), #951 of 1,640 on KOSDAQ (top 58%), #177 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 77%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 64.53B KRW | KR#1,608/2,421 Sec#177/231 |
| Revenue | 14.18B KRW | KR#2,225/2,421 Sec#167/231 |
| Net Income | 1.13B KRW | KR#1,470/2,421 Sec#101/231 |
| Total Assets | 33.28B KRW | KR#2,315/2,421 Sec#216/231 |
| Net Assets | 30.75B KRW | KR#2,165/2,421 Sec#193/231 |
| Employees | 75 | KR#1,840/2,421 Sec#158/231 |
| Value | ||
| P/E | 57.00x | KR#1,435/2,421 Sec#93/231 |
| P/B | 2.10x | KR#1,965/2,421 Sec#146/231 |
| P/S | 4.55x | KR#2,122/2,421 Sec#139/231 |
| EV/EBITDA | 261.39x | KR#1,538/2,421 Sec#107/231 |
| FCF Yield | -0.58% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 3.68% | KR#1,265/2,421 Sec#87/231 |
| ROA | 3.40% | KR#980/2,421 Sec#77/231 |
| Op. Margin | 1.66% | KR#1,427/2,421 Sec#101/231 |
| Revenue Growth | -10.59% | KR#1,939/2,421 Sec#179/231 |
| Earnings Growth | -50.72% | KR#1,057/2,421 Sec#70/231 |
| Financial Health | ||
| Debt Ratio | 8.22% | KR#96/2,421 Sec#21/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | -373.0M KRW | KR#1,249/2,421 Sec#94/231 |
| Cash | 3.01B KRW | KR#2,160/2,421 Sec#202/231 |
| Current Ratio | 9.55x | KR#106/2,421 Sec#25/231 |
| Net Debt/EBITDA | -12.78x | KR#33/2,421 Sec#2/231 |
| Performance | ||
| 1Y Return | -20.28% | KR#1,272/2,421 Sec#86/231 |
| 1M Return | -2.45% | KR#1,516/2,421 Sec#119/231 |
| From 52W High | -43.89% | KR#1,099/2,421 Sec#80/231 |
| 1Y MDD | -41.01% | KR#621/2,421 Sec#44/231 |
| Trading | ||
| Volume | 1,324 shares | KR#2,304/2,421 Sec#221/231 |
| Trading Value | 6.3M KRW | KR#2,322/2,421 Sec#220/231 |
| Foreign Own. | 7.20% | KR#619/2,421 Sec#54/231 |
| Per Share | ||
| EPS | 84 KRW | KR#1,453/2,421 Sec#99/231 |
| BPS | 2,275 KRW | KR#2,006/2,421 Sec#163/231 |
Company Info
PanGen, established in 2010 as a spin-off, was listed on KOSDAQ as a technology growth company in 2016. The company provides biosimilar EPO drug production and sales, biopharmaceutical contract manufacturing, and development technology transfer services, leveraging its PanGen CHO-TECH™ technology and GMP facilities. Its EPO drugs are sold in Asia and Saudi Arabia, and it has completed clinical Phase 3 sample production for Hemophilia A treatment, along with non-clinical trials for macular degeneration treatment and anti-cancer adjuvants. PanGen is headquartered in Suwon-si, Gyeonggi-do.